Earnings history EPS, last 4 quarters −1.00 −0.50 0.00 0.50 Q2 ’22 Q3 ’22 FY ’22 Q1 ’23
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q1 2023 −$0.14 $0.04 —
Annual 2022 −$0.12 $0.12 —
Q3 2022 −$0.92 $0.04 —
Q2 2022 −$0.72 $0.03 —
Next: Nov 19, 2026, estimate $0.00
Company profile Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat
CEO Dr. Adi Mor George Ph.D.
Headquarters Tel Aviv-Yafo, Israel
Employees 0
IPO date Feb 12, 2019
Sector Healthcare
Industry Biotechnology